Although some studies have shown that the use of SGLT-2 inhibitors can result in a slight decrease in potassium levels, especially in patients with CKD, it is important to note that these effects are usually modest and rarely reach clinically significant levels of hypokalemia [47,48,49]. The gene discussed is SLC5A2; the disease is chronic kidney disease.